GW Pharma

Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Endpoints
Ovid Therapeutics
clinical trials
Takeda
Dravet syndrome
Lennox-Gastaut Syndrome
GW Pharma
Flag link:
GW Pharmaceuticals' Epidiolex Wins New FDA Approvals
GW Pharmaceuticals' Epidiolex Wins New FDA Approvals
Motley Fool
GW Pharma
Cannabidiol
Epidiolex
FDA
tuberous sclerosis complex
Flag link:
3 Biotech Stocks With Big Incoming Catalysts
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
FDA
GW Pharma
Epidiolex
filgotinib
Galapagos
Biomarin
valoctocogene roxaparvovec
Flag link:
How GW Pharmaceuticals Hit a Home Run in Q1
How GW Pharmaceuticals Hit a Home Run in Q1
Motley Fool
GW Pharma
earnings
Epidiolex
Flag link:
GW Pharma tops list of UK R&D spenders
GW Pharma tops list of UK R&D spenders
Pharmaforum
GW Pharma
UK
R&D
Flag link:
Zogenix's Positive Clinical Trial Wasn't Positive Enough
Zogenix's Positive Clinical Trial Wasn't Positive Enough
Motley Fool
Zogenix
epilepsy
Lennox-Gastaut Syndrome
clinical trials
Fintepla
GW Pharma
Epidiolex
Flag link:
Zogenix hands GW a win
Zogenix hands GW a win
EP Vantage
Lennox-Gastaut Syndrome
clinical trials
Fintepla
Zogenix
GW Pharma
Flag link:
GW Pharmaceuticals' Preliminary Q4 Revenue of $108 Million Beats Expectations
GW Pharmaceuticals' Preliminary Q4 Revenue of $108 Million Beats Expectations
Motley Fool
GW Pharma
earnings
Flag link:
Where Will GW Pharmaceuticals Be in 5 Years?
Where Will GW Pharmaceuticals Be in 5 Years?
Motley Fool
GW Pharma
cannabindoids
Flag link:
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Yahoo/Benzinga
ASH2019
Roche
Bristol-Myers Squibb
Acadia Pharmaceuticals
Biogen
Cassava Sciences
Alector
GW Pharma
Magenta Therapeutics
Fortress Biotech
Mustang Bio
Bluebird Bio
Flag link:
GW's Epidiolex topped sales predictions, but investors bailed. What gives?
GW's Epidiolex topped sales predictions, but investors bailed. What gives?
Fierce Pharma
GW Pharma
Epidiolex
Flag link:
GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union
GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union
Endpoints
GW Pharma
Europe
Epidyolex
Epidiolex
Flag link:
For GW Pharma CEO Justin Gover, The CBD Trend Started 20 Years Ago
For GW Pharma CEO Justin Gover, The CBD Trend Started 20 Years Ago
Xconomy
GW Pharma
Pharma CEOs
Justin Gover
Flag link:
GW confident epilepsy drug will get NHS funding despite NICE rejection
GW confident epilepsy drug will get NHS funding despite NICE rejection
Pharmaforum
GW Pharma
UK
NHS
NICE
Epidyolex
epilepsy
Flag link:
5 Things You'll Want to Watch With GW Pharmaceuticals
5 Things You'll Want to Watch With GW Pharmaceuticals
Motley Fool
GW Pharma
Epidiolex
Europe
Sativex
regulatory
Flag link:
GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy
GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy
Endpoints
GW Pharma
clinical trials
Epidiolex
cannabindoids
tuberous sclerosis complex
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:
Early Epidiolex sales push up GW Pharma's stock
Early Epidiolex sales push up GW Pharma's stock
BioPharma Dive
Epidiolex
GW Pharma
epilepsy
Flag link:
Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?
Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?
Motley Fool
GW Pharma
Epidiolex
Cannabidiol
clinical trials
Dravet syndrome
Flag link:
GW announces US launch of cannabinoid medicine for seizures
GW announces US launch of cannabinoid medicine for seizures
Pharmaceutical Business Review
GW Pharma
Greenwich. Epidiolex
drug launches
Dravet syndrome
Lennox-Gastaut Syndrome
Flag link:

Pages